Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Rhythm Pharmaceuticals (RYTM) Receivables - Net (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Receivables - Net for 5 consecutive years, with $26.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 40.89% to $26.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.1 million, a 40.89% increase, with the full-year FY2025 number at $26.1 million, up 40.89% from a year prior.
  • Receivables - Net was $26.1 million for Q4 2025 at Rhythm Pharmaceuticals, down from $33.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $33.0 million in Q3 2025 to a low of $862000.0 in Q1 2022.
  • A 5-year average of $14.0 million and a median of $14.7 million in 2024 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: soared 841.65% in 2023, then grew 21.3% in 2025.
  • Rhythm Pharmaceuticals' Receivables - Net stood at $1.0 million in 2021, then soared by 507.22% to $6.2 million in 2022, then soared by 138.87% to $14.9 million in 2023, then grew by 24.52% to $18.5 million in 2024, then skyrocketed by 40.89% to $26.1 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Receivables - Net are $26.1 million (Q4 2025), $33.0 million (Q3 2025), and $26.1 million (Q2 2025).